71.05
-0.42 (-0.59%)
前收盘价格 | 71.47 |
收盘价格 | 71.47 |
成交量 | 127,581 |
平均成交量 (3个月) | 1,794,205 |
市值 | 2,391,545,088 |
市盈率 (P/E TTM) | 66.40 |
预期市盈率 (P/E Forward) | 56.50 |
价格/销量 (P/S) | 6.81 |
股市价格/股市净资产 (P/B) | 12.63 |
52周波幅 | |
利润日期 | 28 Apr 2025 - 2 May 2025 |
营业毛利率 | 8.03% |
营业利益率 (TTM) | 7.11% |
稀释每股收益 (EPS TTM) | 1.07 |
季度收入增长率 (YOY) | 49.80% |
季度盈利增长率 (YOY) | 70.10% |
总债务/股东权益 (D/E MRQ) | 226.72% |
流动比率 (MRQ) | 8.30 |
营业现金流 (OCF TTM) | 48.80 M |
杠杆自由现金流 (LFCF TTM) | -102.77 M |
资产报酬率 (ROA TTM) | 3.10% |
股东权益报酬率 (ROE TTM) | 19.39% |
市场趋势
短期 | 中期 | ||
行业 | Medical Devices (US) | 混合的 | 混合的 |
Medical Devices (全球的) | 混合的 | 混合的 | |
股票 | TransMedics Group, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
分析师共识 | 3.0 |
内部交易活动 | NA |
价格波动 | 4.5 |
技术平均移动指标 | 1.0 |
技术振荡指标 | 2.0 |
平均 | 2.63 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
部门 | Healthcare |
行业 | Medical Devices |
投资方式 | Small Growth |
内部持股比例 | 3.48% |
机构持股比例 | 115.50% |
52周波幅 | ||
目标价格波幅 | ||
高 | 105.00 (Piper Sandler, 47.79%) | 购买 |
中 | 104.50 (47.09%) | |
低 | 104.00 (Canaccord Genuity, 46.39%) | 购买 |
平均值 | 104.50 (47.09%) | |
总计 | 2 购买 | |
平均价格@调整类型 | 80.04 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Piper Sandler | 29 Apr 2025 | 105.00 (47.79%) | 购买 | 92.43 |
Canaccord Genuity | 11 Mar 2025 | 104.00 (46.39%) | 购买 | 67.65 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合